Top of this page
Skip navigation, go straight to the content
Overview investors
Welcome to UCB Investor Relations
Our Investor Relations team aim to serve analysts, shareholders and potential investors with timely, valuable and reliable information.
UCB has the potential to become the next generation biopharma leader
- Powerful and unique combination of biology and chemistry research capabilities
- 12 large and small molecules in clinical development, spanning 14 different types of diseases
- A track record of turning novel ideas into therapeutic and commercial realities
- Solid product life-cycle management
Quick access IR
News List ›
- Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate in Fibromyalgia 20-November-2008
- Cimzia® studies show significant clinical benefits for mono- and combination therapy in patients with rheumatoid arthritis 18-November-2008
- Transparency Notification Of UCB's Reference Shareholders 31-October-2008
- Transparency Declaration by Capital Research and Management Company (CRMC) 31-October-2008
